Optimized outcome of pregnancy in a woman with Glanzmann thrombasthenia with multidisciplinary approach

Sujithradevi Radhakrishnan, Gowri Dorairajan, Murali Subbaiah, Jyotsna Sharma


Glanzmann thrombasthenia (GT), an autosomal recessive disorder of defective platelet aggregation due to abnormalities of platelet receptor GPIIb/IIIa, can result in complication of bleeding during pregnancy. We report multidisciplinary management of a case with optimized outcome. 23 years old short statured (142 cm) primigravida was referred for contracted pelvis at term in labour. She was diagnosed with GT at 12 years of age during evaluation of gum bleeding, easy bruising, and prolonged post traumatic bleeding. She was born of a second-degree consanguineous marriage. At admission she was hemodynamically stable but moderately pale. Her hemoglobin was 8.7 g%, with 4.6 lacs platelets and clotting time of 15 minutes. Multidisciplinary team of hematologist, transfusionist and anesthetist was activated. Arranging single donor platelets in a short notice was challenging. Emergency cesarean section under general anesthesia was performed after transfusing two units packed red blood cell and 2 single donor platelets to deliver an alive male baby of 3.3 kg. Hemostasis was secured with cautery and ligatures. Tranexamic acid infusion and sublingual misoprostol was given prophylactically. she was transfused another 4 random donor platelets during operation and postoperatively. The case details will be presented. GT have normal to high platelet counts though they are normal morphologically, they are dysfunctional. This fact needs to be recognized and referred early to equipped centres. We used component transfusion, active management of third stage and tranexamic acid for optimizing outcome due to haemorrhage. At present, there is lack of consensus regarding optimum treatment of post-partum hemorrhage in patients with GT.


Platelet disorder, Glanzmann thrombasthenia, Pregnancy

Full Text:



Sherer DM, Lerner R. Glanzmann's thrombasthenia in pregnancy: a case and review of the literature. Am J Perinatol. 1999;16(6):297-301.

Botero JP, Lee K, Branchford BR, Bray PF, Freson K, Lambert MP, et al. Glanzmann thrombasthenia: genetic basis and clinical correlates. Haematologica. 2020;105(4):888-94.

Plow EF, Pesho MM, Ma Y-Q. Integrin alpha IIb beta 3. In: Michelson AD, eds. Platelets. Amsterdam, Boston: Academic Press; 2007: 165-178.

French DL. The molecular genetics of Glanzmann's thrombasthenia. Platelets. 1998;9(1):5-20.

Glanzmann E. Hereditary hemorrhagic thrombasthenia: A contribution on the pathology of blood platelets. In: Marshall A, Lichtman JL, Spivak, Boxer LA, Shattil SS, Edward S, eds. Hematology. Amsterdam, Boston: Academic Press; 2000: 113-14.

Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood. 2011;118(23):5996-6005.

Toogeh G, Sharifian R, Lak M, Safaee R, Artoni A, Peyvandi F. Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am J Hematol. 2004;77(2):198-9.

Magudapathi C, Kannan S. Glanzmann's Thrombasthenia Complicating Pregnancy. J Obstet Gynaecol India. 2014;64(1):3-5.

George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood. 1990;75(7):1383-95.

Poon MC, Di Minno G, d'Oiron R, Zotz R. New Insights Into the Treatment of Glanzmann Thrombasthenia. Transfus Med Rev. 2016;30(2):92-9.

Siddiq S, Clark A, Mumford A. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia. 2011;17(5):858-69.

Inc NN. NovoSeven RT [package insert], 2019. Available at: Accessed on 1 June 2021.

Bellucci S, Damaj G, Boval B, Rocha V, Devergie A, Yacoub AI, et al. Bone marrow transplantation in severe Glanzmann's thrombasthenia with antiplatelet alloimmunization. Bone Marrow Transplant. 2000;25(3):327-30.

Ramzi M, Dehghani M, Haghighat S, Nejad HH. Stem Cell Transplant in Severe Glanzmann Thrombasthenia in an Adult Patient. Exp Clin Transplant. 2016;14(6):688-90.

Wilcox DA, Olsen JC, Ishizawa L, Bray PF, French DL, Steeber DA, et al. Megakaryocyte-targeted synthesis of the integrin beta (3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia. Blood. 2000;95(12):3645-51.

Fang J, Hodivala DK, Johnson BD, Du LM, Hynes RO, White GC, et al. Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. Blood. 2005;106(8):2671-9.

Sullivan SK, Mills JA, Koukouritaki SB, Vo KK, Lyde RB, Paluru P, et al. High-level transgene expression in induced pluripotent stem cell-derived megakaryocytes: correction of Glanzmann thrombasthenia. Blood. 2014;123(5):753-7.